The ASCPT Journal Family Welcomes Three New Editors
Clinical Pharmacology & Therapeutics
and Clinical and Translational Science
have welcomed new associate editors to their editorial teams.
Walter Kraft, MD, and Peter Honig, MD, have both joined the CPT
team. Walter is an internist and clinical pharmacologist, currently serving as director of the Thomas Jefferson University (Jefferson) Clinical Research Unit. He is also interested in the development of novel therapeutics in neonatal abstinence syndrome and is the co-primary investigator on the National Institute of General Medical Sciences funded fellowship program in clinical pharmacology at Jefferson. Additionally, he directs the Jefferson Office of Human Research, which oversees the protection of all human subjects for the organization. Walter has held leadership positions in a number of national professional organizations including a stint as treasurer for ASCPT and as a board member on the American Board of Clinical Pharmacology. Presently, he sits on the US Food and Drug Administration (FDA) Advisory Committee for Clinical Pharmacology as well as maintaining a clinical practice in vascular medicine and the treatment of complex venous and arterial thrombotic diseases.
Returning to the CPT
editorial team, Peter is responsible for worldwide safety and regulatory affairs for Pfizer, a position he has held since 2015. Beginning in 2019, he also oversees Pfizer’s China and Japan drug development organizations. (Previous industry positions include time at AstraZeneca and Merck Research Laboratories.) Before joining the industry, Peter founded and was the first Director for the Office of Drug Safety in the US FDA Center for Drug Evaluation and Research (CDER). During his time at CDER he co-authored many FDA guidance documents and received numerous awards and citations. Along with a term as associate editor for CPT
, he also served ASCPT as President, Vice President, Member of the Board of Directors, and Chair of the section on Pharmacoepidemiology, Drug Safety, and Outcomes Research. Since 2003, Peter has been the PhRMA representative for the International Conference on Harmonization (ICH) Steering Committee and is the past co-chair of the ICH Global Cooperation Group. He is a member of the Executive Steering Committee of the FNIH Biomarkers Consortium and a past member of the Science Moving Forward Subcommittee for the FDA Science Board, which examines the FDA’s regulatory science capabilities.
welcomed Ronda Rippley, PhD, who has 24 years of experience as a quantitative scientist focusing on clinical and translational pharmacology within the pharmaceutical industry. Currently, Ronda is Vice President and Head of Clinical Pharmacology at Boston Pharmaceuticals where her work focuses on reducing translational risk and increasing the probability of achieving successful proof of concept. Prior affiliations include Merck, Amgen, and Regeneron. Within ASCPT, she was Vice-Chair of the Biomarkers and Translational Tools community and has contributed on several ad hoc committees, including the Section Futures Task Force and the Strategic Plan Tactical Task Force.
Walter, Peter, and Ronda round out two already robust editorial teams, bringing their expertise and thoughtful feedback to ASCPT’s Journal Family.
Interested in submitting to one of the ASCPT journals? Questions about submission can be sent to email@example.com